Postes, yes, I remember your response. A couple of things to consider. My guess is the patents on Revlimid have a lot less prior art to poke holes into the patents. I mean how much prior art could there be on a drug that deals with stem cells? If you are a pirate ship, you don't take on the aircraft carrier, but you might take on a supply ship, especially if you think you have a shot.
Thanks for the prayers everyone.
News 
Market Data 
Discover 
